NYX-783 not checked

Aptinyx

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).”In the company’s words, NCT04044664 on ClinicalTrials.gov
Tested for
PTSD, Post-Traumatic Stress Disorder
Main trialPhase 2/3
“A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)”In the company’s words, NCT05181995 on ClinicalTrials.gov

Other drugs for PTSD

All 5 drugs for PTSD

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2/3Terminated 30 Mar 2023 Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD
Phase 2Completed 5 Aug 2020 Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow NYX-783

Following is part of Solo: you see every change to NYX-783 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in